Archives des eu projects - Medicen

eu projects


    Osteoporosis is a disease with high occurrence in North-Western Europe. This region is much more affected by bone fractures, with 214 hip replacements per 100,000 inhabitants, compared with an average of 153 in the European Union. This entails significant costs for governments, hence the need to find cost-effective alternative solutions.

    With the emergence of regenerative medicine, new avenues are being explored. These include the use of intelligent implants, such as 3D scaffolds created using a technique called electrospinning (ESP), which could make it possible to regenerate skeletal bone without the need for tissue donors or multiple surgical operations.

    Unfortunately, at present, there are only a few local initiatives in North-Western Europe using ESP technology. The BONE project aims to bring the different actors closer together, by promoting collaboration between 4 research institutes, 4 business support organisations and 5 industrial actors from 6 European countries, creating 15 jobs. Ultimately, the aim is to develop and test in real-world conditions intelligent implants manufactured by ESP and to reach a TRL 8, for significant advances in the field of regenerative medicine.

    PROJECT LEAD: University of Maastricht



    EU FUNDING: €2.04M

    TOTAL BUDGET: €3.41M

    FUNDING YEAR: 2017

    PARTNERS: Fraunhofer Institute for Laser Technology ILT – The Electrospinning Company Limited – Spraybase – Fianium Ltd – Katholieke Universiteit Leuven, represented by KU Leuven Research & Development – University of Lille – Medicen Paris Region

    COUNTRIES: United Kingdom, Netherlands, Ireland, France, Luxembourg, Austria


    The Codex4SMEs project aims to improve healthcare through increased adoption of personalised medicine. Its goal: to be able to provide “the right drug, at the right dose, at the right time, to the right patient”, enabling governments to achieve substantial healthcare savings. To achieve this goal, companion diagnostics (Cdx) are needed, but only a few therapies are currently accompanied by companion diagnostics in Europe.

    This new market could benefit SMEs in North-Western Europe. The region lags behind the United States, which are much more advanced in the field, due to:

    • The European Union regulation (the new directive on in vitro diagnostics only became effective in 2020)
    • High development costs (> €5 million)
    • Project length (> 5 years)

    Codex4SMEs’ goal is to catch up, via a network of 11 partners from 7 countries (Germany, France, Netherlands, United Kingdom, Ireland, Luxembourg and Austria). The idea of the programme is to support around 200 SMEs at each phase of their development: incubation, acceleration and growth. Through support for knowledge transfer, access to samples and validation of biomarkers, 46 companies will manage to increase their TRL by at least one level, and at least 4 of them will achieve the full development of a new product. Finally, the Codex4SMEs project has a long-term ambition, with plans to collect more than 100 letters of intent from future partners.

    PROJECT LEAD: BioRegio STERN Management GmbH



    EU FUNDING: €1.8M

    TOTAL BUDGET: €3.13M

    FUNDING YEAR: 2017

    PARTNERS: BioRegio STERN Management GmbH – University of Leicester – BOM Holding BV – Innovation and Management Centre Limited T/A WestBIC – InnovationQuarter – Medicen Paris Region – Integrated BioBank of Luxembourg – CÚRAM, Research Centre for Medical Devices – Biobank Graz (Medical University of Graz)

    COUNTRIES: United Kingdom, Netherlands, Ireland, France, Luxembourg, Austria


    To ensure and continuously improve the delivery of public services, governments need innovation, often developed by private stakeholders. In many cases, these companies develop their solutions on their own, without really interacting with public bodies, and then try to convince them to buy their products and/or services. Unfortunately, this lack of collaboration often results in solutions that are not fully adapted or are not sufficiently profitable. Startups and SMEs end up with stillborn products and with the conviction that the public sector is not an interesting market (although it is estimated to be worth €2,000 billion in Europe, that is almost 20% of the EU GDP).

    PROJECT LEAD: TICBioMed, association promoting the use of information and communication technologies in healthcare in the region of Murcia





    FUNDING YEAR: 2017

    PARTNERS: TICBioMed – Servicio Murciano de Salud – Instituto de Fomento de la Región de Murcia – Réseau des Acheteurs Hospitaliers d’Île-de-France GIP – RESAH – Paris Region Entreprises – Medicen Paris Region – Hospital District of North Ostrobothnia (Pohjois-Pohjanmaan sairaanhoitopiiri kuntayhtyma) – North Ostrobothnia (Pohjois-Pohjanmaan) – Oulun kaupunki – European Regions Research and Innovation Network – University of Oulu

    COUNTRIES: France, Finland, Belgium

  • BLOCKSTART Label-Medicen

    Blockchain could soon transform three of the five most important sectors in North-Western Europe (agri-food, logistics and healthcare), representing a turnover of €600 billion. These industries have major challenges around data sharing between different countries (tracking of goods shipments, medical records sharing, traceability of food products, etc.). In these areas, SMEs are particularly vulnerable to risks associated with data security, cash flow and late payments.

    With blockchain, these exchanges of information are carried out in an automated, efficient and secure way, without the actors involved having to trust each other. But SMEs generally find it difficult to benefit from these advances: they do not have the means to develop their own solution unlike large companies and companies in the finance sector. Nevertheless, there are products for SMEs, but these do not go beyond a TRL 4.

    The Blockstart project aims to bring the full benefits of this technology to small and medium-sized enterprises. Its objective is to develop 4 blockchain solutions, at a TRL 6, and implement them in 12 SMEs, improving operational efficiency by 10%, reducing the cost of data errors by 20% and the cost of data security by 30%.

    To do so, Blockstart will select 60 SMEs from the UK, France, Germany, the Netherlands and Belgium to identify 4 common issues for these companies. Collaboration across countries will help achieve a critical mass, which is essential for blockchain projects. This will allow the development of solutions that are 70% replicable, with only 30% that needs to be customised. The solutions will be co-developed by a multinational team of experts (on business models, security and incubation) and SMEs. In total, 1,710 SMEs will have access to the solutions and test results. 300 of them will adopt the new tools, creating an additional turnover of €100 million and 500 jobs over 5 years, positioning North-West Europe at the forefront of blockchain technology.

    PROJECT LEAD: Brightlands Smart Services Campus (Campus Heerlen Management & Development BV)



    EU FUNDING: €2.96M

    TOTAL BUDGET: €4.94M

    FUNDING YEAR: 2019-2022

    PARTNERS: University of Applied Sciences Windesheim – Medicen Paris Region – East Netherlands Development Agency – Multitel ASBL – BioRegio STERN Management GmbH – University of Surrey – Public Option – ChainPoint B.V.

    COUNTRIES: Netherlands, France, Belgium, Germany, United Kingdom

    Survey :